Literature DB >> 22182837

Developmental stage determines estrogen receptor alpha expression and non-genomic mechanisms that control IGF-1 signaling and mammary proliferation in mice.

Jie Tian1, Thomas R Berton, Stephanie H Shirley, Isabel Lambertz, Irma B Gimenez-Conti, John DiGiovanni, Kenneth S Korach, Claudio J Conti, Robin Fuchs-Young.   

Abstract

Insulin like growth factor-1 (IGF-1) stimulates increased proliferation and survival of mammary epithelial cells and also promotes mammary tumorigenesis. To study the effects of IGF-1 on the mammary gland in vivo, we used BK5.IGF-1 transgenic (Tg) mice. In these mice, IGF-1 overexpression is controlled by the bovine keratin 5 promoter and recapitulates the paracrine exposure of breast epithelium to stromal IGF-1 that is seen in women. Studies have shown that BK5.IGF-1 Tg mice are more susceptible to mammary tumorigenesis than wild-type littermates. Investigation of the mechanisms underlying increased mammary cancer risk, reported here, revealed that IGF-1 preferentially activated the PI3K/Akt pathway in glands from prepubertal Tg mice, resulting in increased cyclin D1 expression and hyperplasia. However, in glands from postpubertal Tg mice, a pathway switch occurred and activation of the Ras/Raf/MAPK pathway predominated, without increased cyclin D1 expression or proliferation. We further showed that in prepubertal Tg glands, signaling was mediated by formation of an ERα/IRS-1 complex, which activated IRS-1 and directed signaling via the PI3K/Akt pathway. Conversely, in postpubertal Tg glands, reduced ERα expression failed to stimulate formation of the ERα/IRS-1 complex, allowing signaling to proceed via the alternate Ras/Raf/MAPK pathway. These in vivo data demonstrate that changes in ERα expression at different stages of development direct IGF-1 signaling and the resulting tissue responses. As ERα levels are elevated during the prepubertal and postmenopausal stages, these may represent windows of susceptibility during which increased IGF-1 exposure maximally enhances breast cancer risk.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22182837      PMCID: PMC3248275          DOI: 10.1172/JCI42204

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  70 in total

1.  Phosphorylation and regulation of Raf by Akt (protein kinase B).

Authors:  S Zimmermann; K Moelling
Journal:  Science       Date:  1999-11-26       Impact factor: 47.728

Review 2.  Protein kinases as mediators of phosphoinositide 3-kinase signaling.

Authors:  A Toker
Journal:  Mol Pharmacol       Date:  2000-04       Impact factor: 4.436

3.  Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway.

Authors:  S Kahlert; S Nuedling; M van Eickels; H Vetter; R Meyer; C Grohe
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

4.  Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumor promotion.

Authors:  J DiGiovanni; D K Bol; E Wilker; L Beltrán; S Carbajal; S Moats; A Ramirez; J Jorcano; K Kiguchi
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

Review 5.  Crosstalk between the insulin-like growth factors and estrogens in breast cancer.

Authors:  D Yee; A V Lee
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-01       Impact factor: 2.673

Review 6.  The PI3K-PDK1 connection: more than just a road to PKB.

Authors:  B Vanhaesebroeck; D R Alessi
Journal:  Biochem J       Date:  2000-03-15       Impact factor: 3.857

7.  Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells.

Authors:  Stephanie Harkey Shirley; Joyce E Rundhaug; Jie Tian; Noirin Cullinan-Ammann; Isabel Lambertz; Claudio J Conti; Robin Fuchs-Young
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

8.  IGF-I and IGFBP-3 polymorphisms in relation to circulating levels among African American and Caucasian women.

Authors:  Aimee A D'Aloisio; Jane C Schroeder; Kari E North; Charles Poole; Suzanne L West; Gregory S Travlos; Donna D Baird
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-24       Impact factor: 4.254

9.  Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis.

Authors:  Chad J Creighton; Angelo Casa; ZaWaunyka Lazard; Shixia Huang; Anna Tsimelzon; Susan G Hilsenbeck; Charles Kent Osborne; Adrian V Lee
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

10.  Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.

Authors:  Mary Jo Lund; Katrina F Trivers; Peggy L Porter; Ralph J Coates; Brian Leyland-Jones; Otis W Brawley; Elaine W Flagg; Ruth M O'Regan; Sheryl G A Gabram; J William Eley
Journal:  Breast Cancer Res Treat       Date:  2008-03-07       Impact factor: 4.872

View more
  10 in total

Review 1.  ERK1/2-RSK regulation of oestrogen homeostasis.

Authors:  Eric B Wright; Deborah A Lannigan
Journal:  FEBS J       Date:  2022-02-17       Impact factor: 5.622

2.  Targeted genome-wide methylation and gene expression analyses reveal signaling pathways involved in ovarian dysfunction after developmental EDC exposure in rats.

Authors:  Aparna Mahakali Zama; Mehmet Uzumcu
Journal:  Biol Reprod       Date:  2013-02-28       Impact factor: 4.285

3.  Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells.

Authors:  Yuzhe Yang; Jie Ying Chan; Nuri A Temiz; Douglas Yee
Journal:  Horm Cancer       Date:  2018-09-18       Impact factor: 3.869

4.  p130Cas over-expression impairs mammary branching morphogenesis in response to estrogen and EGF.

Authors:  Maria del Pilar Camacho Leal; Alessandra Pincini; Giusy Tornillo; Elisa Fiorito; Brigitte Bisaro; Elisa Di Luca; Emilia Turco; Paola Defilippi; Sara Cabodi
Journal:  PLoS One       Date:  2012-12-11       Impact factor: 3.240

Review 5.  The role of the insulin-like growth factor-1 system in breast cancer.

Authors:  Panagiotis F Christopoulos; Pavlos Msaouel; Michael Koutsilieris
Journal:  Mol Cancer       Date:  2015-02-15       Impact factor: 27.401

6.  Glyceollins trigger anti-proliferative effects through estradiol-dependent and independent pathways in breast cancer cells.

Authors:  Sylvain Lecomte; Frederic Chalmel; François Ferriere; Frederic Percevault; Nicolas Plu; Christian Saligaut; Claire Surel; Marie Lelong; Theo Efstathiou; Farzad Pakdel
Journal:  Cell Commun Signal       Date:  2017-06-30       Impact factor: 5.712

7.  Improvement Activity of 1-Deoxynojirimycin in the Growth of Dairy Goat Primary Mammary Epithelial Cell through Upregulating LEF-1 Expression.

Authors:  Shengyue Ji; Ming Liu; Yuping Zhang; Hongfu Zhang
Journal:  Biomed Res Int       Date:  2018-02-19       Impact factor: 3.411

Review 8.  Growth Hormone/Insulin Growth Factor Axis in Sex Steroid Associated Disorders and Related Cancers.

Authors:  Rachel Bleach; Mark Sherlock; Michael W O'Reilly; Marie McIlroy
Journal:  Front Cell Dev Biol       Date:  2021-03-18

Review 9.  Estrogen receptor-α signaling in post-natal mammary development and breast cancers.

Authors:  Marine Adlanmérini; Elodie Chantalat; Mariam Rusidzé; I Raymond-Letron; Surya Cayre; Jean-François Arnal; Marie-Ange Deugnier; Françoise Lenfant
Journal:  Cell Mol Life Sci       Date:  2021-06-22       Impact factor: 9.261

10.  Membrane expression of the estrogen receptor ERα is required for intercellular communications in the mammary epithelium.

Authors:  Laurine Gagniac; Mariam Rusidzé; Frederic Boudou; Stephanie Cagnet; Marine Adlanmerini; Pauline Jeannot; Nicolas Gaide; Frank Giton; Arnaud Besson; Ariane Weyl; Pierre Gourdy; Isabelle Raymond-Letron; Jean-Francois Arnal; Cathrin Brisken; Francoise Lenfant
Journal:  Development       Date:  2020-03-11       Impact factor: 6.862

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.